BiSiChem is developing TGF-¥â inhibitors as a candidate for solid tumors and/or immunotherapy
and applied for the PCT international patent in 2020.
TGF-¥â Inhibitor relates to a series of substituted heterocyclic compounds which are inhibitors
of the transforming growth factor-¥â (TGF-¥â) type I receptor (ALK5) and/or the activin type I receptor (ALK4).
The inhibitor plays a key role in improving the surrounding environment to ensure that immune cells attack cancer cells.
In normal cells, TGF-¥â plays a crucial role in the maintenance of cell homeostasis and organ formation,
including cell growth & death, differentiation, immunity and epithelial-mesenchymal transition(EMT)
in various biological processes.
However, abnormal signal transduction of TGF-¥â causes life-threatening diseases such as cancer, fibrosis,
NASH, and diabetes. Especially in the tumor micro environment, it suppresses immunity, promotes cancer cell metastasis,
and induces anti-cancer drugs resistance.